GLP-1 agonists like Wegovy and Zepbound offer far greater weight loss than older drugs like orlistat or phentermine, but they come with higher costs, injections, and side effects. Here's how they compare - and who they really work for.
Tirzepatide (Zepbound) is a dual incretin therapy that targets both GLP-1 and GIP receptors to promote significant weight loss. It outperforms older GLP-1 drugs like semaglutide, with users losing up to 22.4% of body weight. Learn how it works, what to expect, and who it's for.
